Amphastar Pharmaceuticals, Inc.

The company is a biopharmaceutical business that develops, manufactures, and commercializes injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients. Its commercial portfolio includes over twenty-five prescription drugs and an over-the-counter asthma inhaler, Primatene MIST. Key offerings comprise BAQSIMI nasal powder for severe hypoglycemia, generic glucagon, epinephrine, lidocaine, enoxaparin, naloxone, and insulin active pharmaceutical ingredients. It also develops biosimilar insulin candidates and proprietary therapeutics. The company sells its products primarily to healthcare institutions, including hospitals, clinics, long-term care facilities, and medical offices, as well as to retail pharmacies through wholesale distributors and group purchasing organizations.

The business operates internationally, distributing products such as BAQSIMI across the United States and twenty-six foreign markets. Its physical infrastructure encompasses sixty-nine owned or leased buildings spanning 2.5 million square feet across six locations in the United States, France, and China. Facilities are situated in Rancho Cucamonga and South El Monte, California; Canton, Massachusetts; Éragny-sur-Epte, France; and Nanjing, China. The provided text does not specify a corporate headquarters.

Summary of the business section of Amphastar Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 163 employees dedicated to research and development with expertise in areas such as pharmaceutical formulation, process development, toxicity studies, analytical, synthetic, and physical chemistry, drug delivery, device development, equipment and engineering, clinical research statistical analysis, etc.”